Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rose 2.4% during mid-day trading on Tuesday . The stock traded as high as $67.50 and last traded at $66.59, with a volume of 255,668 shares trading hands. The stock had previously closed at $65.02.

RARE has been the topic of several research reports. JPMorgan Chase & Co. set a $110.00 price objective on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Monday, August 8th. Credit Suisse Group AG restated a “buy” rating and set a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 25th. Canaccord Genuity restated a “buy” rating and set a $120.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 15th. Jefferies Group restated a “buy” rating and set a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, May 10th. Finally, Leerink Swann restated a “buy” rating and set a $86.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Thursday, August 25th. Three research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $99.17.

The stock’s market capitalization is $2.63 billion. The stock’s 50-day moving average price is $61.04 and its 200 day moving average price is $62.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same period last year, the business earned ($0.83) earnings per share. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.93) earnings per share for the current year.

In related news, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $67.61, for a total value of $1,352,200.00. Following the sale, the chief executive officer now directly owns 493,244 shares in the company, valued at $33,348,226.84. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Ultragenyx Pharmaceutical stock. Trexquant Investment LP bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,010,000.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.